“When I think about genetic testing, I think about screening,” says David C. Collymore, MD, MBA. In his opinion, genetic testing finds application in “screening large populations of people to see who is susceptible to certain illnesses.”
Genomic testing, on the other hand, has application following diagnosis, according to Dr Collymore. “When an illness has been identified, what treatment can be tailored to improve the outcomes of that individual? One is a screening mindset and the other a treatment mindset,” Dr Collymore explained.
It is necessary, though, to consider the cost-to-benefit ratio for these tests, he advised. “With any screening modality, you want to ensure that the cost of the screening mechanism, over a broader population, makes it an effective [to detect] illnesses in that broader population,” said Dr Collymore.
Improving SMA HRQOL Must Address Patient and Caregiver Well-being
February 7th 2023Data from 2 prospective studies showed correlations between impaired patient health-related quality of life (HRQOL) and disease severity, as well as correlations between the health of caregivers and their HRQOL and caregiver burden.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
NCCN Launches Pilot Project Aiming to Measure, Implement Health Equity in Cancer Care Practices
February 4th 2023Five leading academic cancer centers are assessing the feasibility of implementing the Health Equity Report Card pilot project as a tool that can both meaningfully and feasibly measure and report on equitable care practices.
Read More
A Look at Racial Disparities in US HPV Vaccine Uptake
March 1st 2022On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.
Listen
FDA Approves Sacituzumab Govitecan for Pre-Treated HR+/HER2- Metastatic Breast Cancer
February 3rd 2023The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512